Yüklüyor......
The Anti-CD38 Antibody Therapy in Multiple Myeloma
Multiple myeloma (MM) is the second-most common hematologic malignancy after diffuse large B-cell lymphoma. Despite the improvement in response and survival rates following the introduction of novel therapies, only a few patients are cured, and the majority of MM patients experience several relapses...
Kaydedildi:
| Yayımlandı: | Cells |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6952883/ https://ncbi.nlm.nih.gov/pubmed/31842517 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells8121629 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|